StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Non-GAAP diluted earnings (loss) per share by Quarter

Non-GAAP diluted earnings (loss) per share ($/sh) ($)

QuarterlyAnnual

Gilead Sciences Non-GAAP diluted earnings (loss) per share: -$8.45 in Q2 2026, down 641.7% from a year earlier. That is the lowest of the 39 quarters on record here.

Latest, Q2 2026
-8.45
Period ended Jun 30, 2026
Change on a year earlier
-641.7%
1.56 in Q2 2025
History
39 quarters
Since Q4 2016
Sources
33
Documents cited below

Where the Q2 2026 figure comes from

“|| Diluted (loss) earnings per share | $ | (8.45) | $ | 1.56 | $ | (6.82) | $ | 2.61”

Source: Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗

Reported in Form 8-K GAAP to Non-GAAP Reconciliation.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNon-GAAP diluted earnings (loss) per share ($/sh) ($)Year on yearSource
Q2 2026Jun 30, 2026-8.45-641.7%Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 20261.61+54.8%Form 8-K (exhibit991earningspressrel.htm, filed 2026-05-07) ↗
Q4 2025Dec 31, 20251.86-2.1%Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
Q3 2025Sep 30, 20252.47+22.3%Form 8-K (exhibit991earningspressrel.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 20251.56-22.4%Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 20251.04-178.8%Form 8-K (exhibit991earningspressrel.htm, filed 2026-05-07) ↗
Q4 2024Dec 31, 20241.90+10.5%Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
Q3 2024Sep 30, 20242.02-11.8%Form 8-K (exhibit991earningspressrel.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 20242.01+50.0%Form 8-K (exhibit991earningspressrel.htm, filed 2025-08-07) ↗
Q1 2024Mar 31, 2024-1.32-196.4%Form 8-K (exhibit991earningspressrel.htm, filed 2024-04-25) ↗
Q4 2023Dec 31, 20231.72+3.0%Form 8-K (exhibit991earningspressrel.htm, filed 2025-02-11) ↗
Q3 2023Sep 30, 20232.29+20.5%Form 8-K (exhibit991earningspressrel.htm, filed 2024-11-06) ↗
Q2 2023Jun 30, 20231.34-15.2%Form 8-K (exhibit991earningspressrel.htm, filed 2024-08-08) ↗
Q1 2023Mar 31, 20231.37-35.4%Form 8-K (exhibit991earningspressrel.htm, filed 2024-04-25) ↗
Q4 2022Dec 31, 20221.67+142.0%Form 8-K (exhibit991earningspressrel.htm, filed 2024-02-06) ↗
Q3 2022Sep 30, 20221.90-28.3%Form 8-K (exhibit991earningspressrel.htm, filed 2023-11-07) ↗

Cite this data

StockData. (2026). Gilead Sciences Non-GAAP diluted earnings (loss) per share ($), quarterly Q4 2016–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/ng-eps-diluted

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.